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Abstract
Background. Gliomas are the most common type of primary brain tumor and one of many cancers where males
are diagnosed with greater frequency than females. However, little is known about the sex-based molecular differences in glioblastomas (GBMs) or lower grade glioma (non-GBM) subtypes. DNA methylation is an epigenetic
mechanism involved in regulating gene transcription. In glioma and other cancers, hypermethylation of specific
gene promoters downregulates transcription and may have a profound effect on patient outcome. The purpose of
this study was to determine if sex-based methylation differences exist in different glioma subtypes.
Methods. Molecular and clinical data from glioma patients were obtained from The Cancer Genome Atlas and
grouped according to tumor grade and molecular subtype (IDH1/2 mutation and 1p/19q chromosomal deletion).
Sex-specific differentially methylated probes (DMPs) were identified in each subtype and further analyzed to determine if they were part of differentially methylated regions (DMRs) or associated with differentially methylated DNA
transcription regulatory binding motifs.
Results. Analysis of methylation data in 4 glioma subtypes revealed unique sets of both sex-specific DMPs and DMRs in
each subtype. Motif analysis based on DMP position also identified distinct sex-based sets of DNA-binding motifs that
varied according to glioma subtype. Downstream targets of 2 of the GBM-specific transcription binding sites, NFAT5
and KLF6, showed differential gene expression consistent with increased methylation mediating downregulation.
Conclusion. DNA methylation differences between males and females in 4 glioma molecular subtypes suggest an
important, sex-specific role for DNA methylation in epigenetic regulation of gliomagenesis.

Key Points
• Male and female glioma patients exhibit genome-wide DNA methylation differences.
• Glioma molecular subtypes display distinct sex-based methylation patterns.
• Sex-based methylation differences may influence gliomagenesis and prognosis.
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Importance of the Study

Gliomas represent about 81% of the malignant brain and
central nervous system (CNS) tumors in the United States
with more than 100 000 cases diagnosed between 2011
and 2015.1 Classification of these heterogeneous tumors
is based on World Health Organization (WHO) criteria and,
beginning in 2016, incorporates both molecular as well as
histological characteristics.2 More than 55% of gliomas are
categorized as WHO grade IV glioblastoma (GBM), which
have the worst prognosis, with a median survival of less
than 2 years.1,3 Gliomas in WHO grades I–III categories are
considered lower grade gliomas (non-GBM) and vary in
terms of overall survival based on molecular subtype.1,2 Of
key importance in predicting outcome for these non-GBM
patients, is the presence of mutations in the isocitrate dehydrogenase genes 1 or 2 (IDH1/2) which correspond to longer
survival. IDH1/2 mutations may also be found in GBM, although strictly in instances of clear tumor progression from
lower grades, and in only about 10% of GBMs.2 Non-GBM
prognosis is also greatly influenced by deletions in the short
arm of chromosome 1 and the long arm of chromosome 19
(1p/19q co-deletion) which further prolong survival.4,5 While
other genes play a role in response to treatment and outcome,4–6 IDH1/2 mutation and 1p/19q co-deletion are hallmark genetic features in the 2016 CNS WHO and “trump”
discordant histological assessment.2
As with many other cancers,1,7–10 the incidence of GBMs
and non-GBMs is higher in males than females. In GBMs
the incidence rate is 1.6 times higher in males compared
to females.1,11 Furthermore, the age-adjusted median survival of males is 17.5 months compared to 20.4 months
in females with GBM.3 For patients with non-GBMs in the
United States, males also have a higher incidence rate
than females, about 1.3 times higher for several types of
astrocytomas and oligodendrogliomas,1 although these
differences in incidence rates are not mirrored by differences in survival time.3 The sex differences in gliomas are
evident in all age groups, ruling out the explanation that
they are solely the result of sex hormones.1,10,12
Several studies have shown an association between
specific DNA methylation patterns and patient outcome,
both in gliomas and in other cancers.13–16 Cancer genomes
in general are hypermethylated relative to normal cells,
particularly in the promoter regions of protein-coding
genes.17–19 A working hypothesis is that hypermethylation

We show that when analyzing DNA methylation data by sex and molecular subtype, distinct DNA methylation patterns emerge. This
work highlights the importance of parallel,
but separate analyses of male and female
data. Improved insights into the molecular
differences between male and female glioma
patients will be vital for understanding the discrepancies in gliomagenesis rates and prognosis, and may lead to improved treatments
for both sexes.

in the promoter regions of tumor suppressor genes leads
to downregulation of proteins needed to maintain proper
growth control. The role of methylation in epigenetic regulation of the genome has focused primarily on cytosine–
guanine dinucleotides (CpGs). In general, CpGs appear at
low frequency throughout the genome, but are enriched in
CpG Islands. CpG islands are defined as regions of the genome of at least 500 base pairs with more than 55% GC
content19,20; nearly 70% of annotated gene promoter regions are vested with CpG islands.21 In addition to CpG islands, other parts of the genome have been characterized
as shores (flanking regions of up to 2 kb), shelves (2–4 kb
regions farther out from the islands), and openseas (yet
more distant regions with isolated CpGs).19,20,22 Recent
studies have indicated that in addition to methylation of
CpG islands, methylation of CpG shores plays a key role in
gene regulation.13
The importance of epigenetic methylation in cancer
progression is illustrated by the CpG Island Methylator
Phenotype (CIMP), a hypermethylation pattern detected
in the glioma field and in other cancers.14–16,23,24 In glioma
patients, the G-CIMP pattern is most common in younger,
non-GBM patients with IDH1/2 mutant, non-co-deleted
1p/19q chromosomes.14,25 Patients with CIMP-positive tumors, “G-CIMP-positive,” have significantly improved survival compared to G-CIMP-negative patients.5,14,15,25
Based on these studies, we hypothesized that epigenetic
methylation differences in males and females contribute to
the differing rates of overall glioma occurrence, treatment
responses, and survival differences among gliomas based
on molecular subtype. Thus, we investigated DNA methylation patterns in molecular subtypes of gliomas by sex to
determine if any common characteristics could explain the
known sex-based differences in gliomas.

Materials and Methods
Patient Data
Clinical and molecular data from tumor resections and
biopsies were collected from the NIH Genomic Data
Commons for 587 glioma participants from The Cancer
Genome Atlas (TCGA) PanCancer Atlas Cohort (https://
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Significantly more males than females are
diagnosed with gliomas, and this sex-based
bias occurs throughout life. Furthermore, the
overall survival of males is significantly shorter
compared to females with GBM. However, little
is known about the molecular differences that
may explain the sex-based differences in incidence and survival. Here we have investigated
this discordance by examining epigenetic differences between male and female glioma
patients, stratified by molecular subtype.
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Data were analyzed using R v3.5.3 by molecular subtype and sex. Clinical data were summarized using the
“tableone” package. Survival analyses were performed
using the “survival” and “survminer” packages in R. The
Kaplan–Meier method was used for generating unadjusted
survival curves, and the contribution of age to overall survival was assessed using Cox proportional hazards regression models. In all cases, log-rank P-values <.05 were
considered statistically significant.
Differentially methylated probes (DMPs) and differentially methylated regions (DMRs) were identified using the
R package “ChAMP” v2.12.4.27 DMPs with False Discovery
Rate (FDR) adjusted P-values <.05 were considered statistically significant. DMPs hypermethylated in males relative to females are referred to as HyperMale, and DMPs
hypermethylated in females compared to males are referred to as HyperFemale. DMRs were identified using the
Bumphunter method in ChAMP using the default parameters. ChAMP uses the Benjamini and Hochberg method
for FDR estimation to identify differentially methylated
sites between males and females. Autosomal probes and
regions with FDR corrected P-values <.05 were considered
statistically significant. Probes were annotated using the
Infinium HumanMethylation450 Bead Chip annotation
file, which provides information regarding a probe’s location in known enhancer or DNase I hypersensitive site

Results
Samples and Clinical Data
Clinical data are summarized in Table 1. After adjusting
for age, median overall survival times were significantly
longer in the IDHwt GBM females (N = 31; 8.3 months,
95% CI: 6.6–15.3) compared to IDHwt GBM males (N = 44;
5.4 months, 95% CI 4.7–12.0) (log-rank P-value = .01).
Non-GBM patients were divided into 3 groups based on
IDH1/2 mutation and 1p/19q co-deletion status. Female
IDHwt non-GBM patients (N = 42) had an age-adjusted
median overall survival of 21.2 months (95% CI 16.8–60.0)
versus 21.0 months (95% CI 16.4–27.2) for IDHwt nonGBM males (N = 52, Table 1). Although the age-adjusted
median overall survival times were similar for these 2
groups, survival rates diverge at later times resulting in
significantly different age-adjusted overall survival rates
(log-rank P-value = .01) (Supplementary Figure 1). One
hundred seventy-two patients had an IDH1/2 mutation and
were co-deleted for 1p/19q (IDHmut-codel). Due to the low
number of deaths during the follow-up period, an ageadjusted median overall survival time could not be determined for either IDHmut-codel females (N = 78) or males
(N = 94) (Table 1, Supplementary Figure 1). The largest
group of non-GBMs (N = 246) were IDHmut and did not
have the 1p/19q co-deletion (IDHmut-non-codel). Female
IDHmut-non-codel non-GBM patients (N = 109) had an
age-adjusted median overall survival of 60 months (95%
CI 60–NA) compared to 368 months (95% CI 60–NA) for
males (N = 137) in this subtype. Inspection of age-adjusted
Kaplan–Meier overall survival plots revealed male and female survival plots crossing multiple times throughout the
course of the disease (Supplementary Figure 1). Despite
the apparent difference in median overall survival, there
was no significant sex-specific survival difference between
female and male IDHmut-non-codel non-GBM patients
(log-rank P-value = .41) in this subtype (Supplementary
Figure 1).
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Data Analysis

(DHS) based on experimental data from ENCODE. The reported sensitivity of the Infinium HumanMethylation450
Bead Chip assay is 0.20,20 thus probes with a Δβ magnitude 0.20 or greater were considered unlikely to be
false-positives. Hypergeometric Optimization of Motif
Enrichment (HOMER) v4.9 (http://homer.ucsd.edu/homer/)
was employed to search for known and de novo DNA
binding sequences (8–20 bp motifs) with the perl script
findMotifGenome.pl using the following criteria: hg19 genome, 200 bp upstream and downstream from each CpG
site, and with expected genome-wide distribution of 450K
probes as background. HOMER results for “de novo” motifs with P-values <1e−10 were compared to previously
published versions to determine those that represented differentially methylated motifs. HOMER input files and raw
outputs reported in this paper can be found at https://data.
mendeley.com/datasets/rm588t26dp/1. Venn diagrams
were generated using an online tool available at http://bioinformatics.psb.ugent.be/webtools/Venn/. Figure 1 is a
schematic of the analysis workflow.

Neuro-Oncology
Advances

www.cancer.gov/tcga). The TCGA data were collected prior
to the 2016 CNS WHO Classification system and include
histologic phenotypes, such as oligoastrocytomas, no
longer favored. (The historical histologic types entered
into TCGA for each of the 3 non-GBM subtypes are shown
in Supplementary Table 1.) For this study, we relied on
IDH1/2 mutation and 1p/19q co-deletion status to sort nonGBM glioma samples into 3 groups for consistency with
the molecular descriptions of the main glioma categories
described in the 2016 CNS WHO revision.2 Data were limited to N = 75 untreated primary IDH1/2 wild-type (IDHwt)
GBM patients and N = 512 non-GBM patients for which
complete Illumina Human Methylation 450K and clinical
data were available. Two GBM patients with IDH1/2 mutations and 3 with unknown IDH1/2 status were excluded
from this study due to the small sample size. Ninety-four
of the non-GBM were IDHwt, 172 were IDH1/2 mutant
and co-deleted for 1p/19q (IDHmut-codel), and 246 were
IDH1/2 mutant and did not have the 1p/19q co-deletion
(IDHmut-non-codel).
PanCancer TCGA clinical data, DNA methylation level
3 PanCancer TCGA data, and RNA sequencing level 3
PanCancer TCGA are described in the work of Malta et al.26
Previously published updates to TCGA glioma patient survival data were also used.15 The DNA methylation data utilized for this study were normalized and batch corrected
level 3 data that underwent preprocessing as part of the rigorous PanCancer TCGA analyses as previously described.26
β-values range from 0 to 1, with 0 indicating no DNA methylation and 1 indicating complete DNA methylation. RNA
sequencing level 3 TCGA data have been batch corrected,
processed, and normalized as previously published.26
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TCGA Glioma Data
GBM

IDHwt GBM
44 Males
31 Females

IDHwt non-GBM
52 Males
42 Females

non-GBM

IDH mutant-non-codel
non-GBM
137 Males
109 Females

Compare probe methylation levels by sex → DMPs
IDHwt GBM
254 Male DMPs
57 Female DMPs

IDHwt non-GBM
59 Male DMPs
450 Female DMPs

IDH mutant-codel
non-GBM
420 Male DMPs
279 Female DMPs

IDH mutant-non-codel
non-GBM
16 083 Male DMPs
426 Females DMPs

Identify DMRs
IDHwt GBM: 12
IDHwt non-GBM: 8
IDHmut-codel non-GBM: 19
IDHmut-non-codel non-GBM: 56

Compare DMP distribution by location
(island, shore, ...), Enhancer/Other,
DHS/Other

Identify DNA binding motifs
via HOMER
de novo Motifs p-value < 1e–10,
acceptable alignment
IDHwt GBM 33 Male, 23 Female
IDHwt non-GBM 5 Male, 45 Female
IDHmut-codel non-GBM 52 Male, 54 Female
IDHmut-non-codel non-GBM 102 Male, 76 Female

Identify DMPs with |Δβ| ≥ 0.2
IDHwt GBM:
1 male DMP, chr6
3 female DMP, chr 20

IDHwt non-GBM:
3 female DMP, chr 20
**1 female DMP, chr 12

IDHmut-codel non-GBM:
1 male DMP, chr 8
1 male DMP, chr 13
**1 female DMP, chr 12

Figure 1. Summary of workflow and key results. Glioma data were obtained from TCGA and divided as indicated into 4 subtypes for analysis.
Methylation levels at CpG probes in males and females were compared and those with adjusted P-values <.05 were considered significant. Probes
hypermethylated in males compared to females are referred to as “HyperMale DMPs” while probes hypermethylated in females relative to males
were termed “HyperFemale DMPs.” Some probes, including some annotated to genes, were found in all 4 glioma subtypes, while others were
unique to a given subtype. Significant DMPs in each subtype were compared to each other in terms of distribution throughout the genome (island,
shore, shelf, opensea), correspondence to enhancer regions, and localization to DHSs. DMP locations were also used to identify differentially methylated regions throughout the genomes of each subtype. DMPs with |Δβ| ≥ 0.20 were further examined. ** Denotes DMP on chromosome 12 shared
by IDHwt non-GBM and IDHmut-codel non-GBM subtypes. Potential transcription factor binding motifs were determined using HOMER. Those
de novo motifs with P-values <1e−10 and that align well with known binding sites for a given transcription factor merit further investigation. DHS,
DNase I hypersensitive site; DMP, differentially methylated probes; TCGA, The Cancer Genome Atlas.
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IDH mutant-codel
non-GBM
94 Males
78 Females
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Summary of Patient Data by Glioma Molecular Subtype and Sex

IDHwt GBM

Female

Male

N

31

44

Mean age in yrs (SD)

65.26 (11.89)

63.00 (8.75)

39–85

47–83

Adjusted median overall survivalc (months) [95% CI]

8.3 [6.6–15.3]

5.4 [4.7–12.0]

.01b

31 (100.00)

44 (100.00)

NA

N

42

52

Mean age in yrs (SD)

49.18 (14.31)

53.83 (14.89)

24–74

21–87

21.2 [16.8–60.0]

21.0 [16.4–27.2]

.01b

No

22 (52.4)

32 (61.5)

.50d

Yes

20 (47.6)

20 (38.5)

N

78

94

Mean age in yrs (SD)

46.44 (13.06)

44.12 (12.50)

Age range

20–74

17–75

Adjusted median overall survivalc (months) [95% CI]

NA [NA–NA]

NA [68.4–NA]

<.01b

No

7 (9.0)

10 (10.6)

.91d

Yes

No

Adjusted median overall

survivalc

(months) [95% CI]

Living (%)

Living (%)
IDHmut-non-codel
nonGBM

71 (91.0)

84 (89.4)

N

109

137

Mean age in yrs (SD)

38.65 (10.95)

37.23 (10.88)

.14a

.24a

.31a

Age range

18–73

14–70

Adjusted median overall survivalc (months) [95% CI]

60 [60–NA]

368 [60–NA]

.40b

No

22 (20.2)

21 (15.3)

.41d

Yes

87 (79.8)

116 (84.7)

Living (%)

Two IDHwt GBM patients, 1 male and 1 female, were missing 1p/19q co-deletion status data. Age data were missing for 3 females and 4 males in
the IDHwt non-GBM subtype.
aP-value from t test.
bP-value from log-rank test.
cAdjusted for by age.
dP-value from chi-square test.

  
DMPs by Glioma Molecular Subtype and Sex
The number of DMPs varied for each glioma subtype
(Figure 2). In IDHwt GBMs, 254 DMPs were hypermethylated
in males compared to females (HyperMale DMP) while
only 57 DMPs were hypermethylated in females relative to
males (HyperFemale DMP). In non-GBMs, 59 HyperMale
DMPs and 450 HyperFemale DMPs were found in the IDHwt
subtype, 420 HyperMale DMPs and 279 HyperFemale
DMPs were found in the IDHmut-codel subtype, and 16 083
HyperMale DMPs and 426 HyperFemale DMPs were found
in the IDHmut-non-codel subtype (Supplementary File 1).
The IDHmut-non-codel tumors were notable for an extremely large number of HyperMale DMPs. Of the 16 083
HyperMale DMPs found in IDHmut-non-codel patients,
more than 80% had │Δβ│ values less than 0.05 which may
indicate increased heterogeneity for these patients relative
to the other 3 groups.
The majority of DMPs hypermethylated in males relative to females were unique to a particular glioma subtype,
although 34 probes were significantly hypermethylated

in males in all 4 glioma subtypes (Figure 2). Similarly in
females, each subtype was characterized by a primarily
unique set of probes hypermethylated in females compared to males, but all 4 glioma subtypes shared 25 probes
in common (Figure 2). Using the Illumina 450K probe annotation package, we found 25 genes that were associated
with the DMPs hypermethylated in males and 17 genes
associated with DMPs hypermethylated in females in all
4 glioma subtypes (Supplementary Table 2).28 The genes
associated with HyperMale DMPs in all glioma subtypes
were enriched for cell cycle phase transition genes (TFPD1,
RAD21, TUBB4A, ATAD5, and FOXN3). Genes associated with HyperFemale DMPs common to all glioma subtypes were enriched for transcriptional regulators (TLE1,
POUF3F2, CDK6, ARID1B, PRDM4, POLDIP3, and DACH1).
We also assessed DMPs for location in the genome
(Figure 3). DMPs hypermethylated in females were primarily localized to CpG islands across the glioma subtypes:
60% in IDHwt GBM, 25% in IDHwt non-GBMs, 61% in
IDHmut-codel non-GBMs, and 48% in IDHmut-non-codel
non-GBMs. In contrast, probes differentially methylated in
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Age range

IDHmut-codel
non-GBM

.35a

Age range
Living (%)
IDHwt non-GBM

P-value
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IDHwt
non-GBM

0
0

185

268
12

34

0

15733

13

6
25

9
1

3
0

70

Genes
314

6324

Males vs. Females

t
Hw
ID BM
G

IDHwt
non-GBM

IDHmut-codel
non-GBM

247

111
11

0
1

10

27
15

17

1
7

167
8

0

1

0

Females vs. Males

Females vs. Males

Figure 2. Intersection of differentially methylated probes (DMPs) and genes in each of the 4 glioma subtypes. DMPs hypermethylated in
males relative to females (top left) and DMPs hypermethylated in females relative to males (bottom left). All probes with a significant FDR adjusted P-value (<.05) were compared to determine those shared between different glioma subtypes and those unique to a particular subtype.
Distribution of common and unique genes assigned to DMPs hypermethylated in males relative to females (top right) or in females relative to
males (bottom right).
  

males were primarily located in openseas regions (>4 kb
from CpG islands): 35% in IDHwt GBM, 41% in IDHwt
non-GBMs, 54% in IDHmut-codel non-GBMs, and 56%
in IDHmut-non-codel non-GBMs. We assessed also the
number of DMPs mapped to known enhancer regions and
to DNase I hypersensitive sites (DHS) to probe potential
functional consequences of sex-specific differential methylation (Figure 3). Across all glioma subtypes, a higher percentage of probes hypermethylated in males were located
in enhancer regions compared to probes hypermethylated
in females. In contrast, with the exception of IDHwt nonGBMs, probes hypermethylated in females mapped to
known DHS at a higher rate than those hypermethylated
in males.
Several DMPs were identified where methylation differed at least 20% between males and females (|Δβ| ≥ 0.2)
(Figure 4, Supplementary Table 3). Four DMPs met this
criterion in the IDHwt GBM and non-GBM subtypes, and
3 DMPs were found in the IDHmut-codel subtype. None
of the DMPs detected in the IDHmut-non-codel category

differed by this magnitude. The 3 HyperFemale DMPs in the
IDHwt GBM group all mapped to the pseudogene FRG1B
on chromosome 20, including 1 (cg07753967) located
within 1500 bases of the putative transcriptional start site.
The male IDHwt GBM DMP, cg06897628, was located in an
opensea on chromosome 6 at position 28762544. Three additional HyperFemale DMPs were found in the IDHwt nonGBMs on chromosome 20, along with 1 HyperFemale DMP,
cg08037478, on chromosome 12. The IDHmut-codel nonGBMs had 2 notable HyperMale DMPs, 1 on chromosome
8 and 1 on chromosome 13 which maps to the 3′UTR of
a gene for alpha-1,2-mannosyltransferase (ALG11). In addition, IDHmut-codel non-GBMs share the HyperFemale
DMP cg08037478 with IDHwt non-GBMs.

DMRs by Glioma Molecular Subtype and Sex
We considered the overall genomic context of methylation in each subtype by examining DMRs. DMRs
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23.23%

32.20%

24.67%

22.14%

59.65%
24.22%

29.92%
23.73%
3.39%

11.42%

B

F

39.56%

F

18.64%

17.33%

3.51%
22.83%

81.36%

77.17%

55.50%

4.46%

5.38%
23.47%

M

F

11.90%

11.83%

M

F

6.57%

82.67%

88.10%

Enhancer
Other

93.43%

88.17%
67.72%

F

M
9.45%

21.05%
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Figure 3. Distribution of DMPs hypermethylated in males relative to females (“M”), and in females relative to males (“F”) in the 4 glioma subtypes. (A) Distribution of probes characterized as belonging to island, shore, shelf, and opensea regions in the genome. (B) Percentages of probes
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elsewhere in the genome. The number of DMPs in each category is indicated.
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Figure 4. DMPs found for each glioma subtype that differ by a magnitude of 0.2 or more. Solid bars indicate probes hypermethylated in males
relative to females. Hatched bars indicate probes hypermethylated in females relative to males. The chromosomal location along with available
information regarding correlated genes is shown for each. One probe, cg08037478, was common to both the IDHwt non-GBM and IDHmut-codel
non-GBM subtypes (circled). DMP, differentially methylated probe; GBM, glioblastoma.
  

ranging in length from 37 to over 1500 bases were
found throughout the genome among the 4 subtypes
(Supplementary File 2). The number of DMRs detected for
the 4 subtypes included 12 DMRs on 8 different chromosomes for IDHwt GBMs, 8 DMRs across 6 different
chromosomes for IDHwt non-GBM, 19 DMRs over 10
different chromosomes in the IDHmut-codel non-GBM,
and 56 DMRs spanning 18 chromosomes in the IDHmutnon-codel non-GBM group (Supplementary File 2). While
the functional consequences of the identified DMRs
cannot be ascertained without additional transcriptomic
data analysis, they provide further evidence that each
glioma subtype is distinct. Most DMRs were unique to
a particular glioma subtype but DMRs common to 2 or
3 subtypes were identified. For instance, IDHwt GBMs,
IDHmut-codel non-GBMs, and IDHmut-non-codel nonGBMs all shared a DMR on chromosome 6 that lies in
close proximity to 3 closely related members of the heat
shock protein 70 family (Hsp70): HSPA1A, HSPA1B, and
HSPA1L (Supplementary File 2). IDHwt GBM and IDHwt
non-GBMs shared a DMR in common on chromosome
13 that coincides with the middle of a noncoding RNA,
RNF219-AS1. DMRs common to both IDHmut-non-codel
and IDHwt non-GBMs were found on chromosome 2,
mapping to the PAX8 gene, and on chromosome 6 corresponding to pseudogene RP11-373N24.2 (Supplementary
File 2). Both IDHmut non-GBM subtypes also shared a
DMR on chromosome 20, overlapping a central portion of
non-protein coding gene FRG1B.
In addition to genes mentioned above, the DMRs specific to the IDHwt GBM subtype mapped to FAM163A,
neuroblastoma-derived secretory protein, on chromosome

1 and 3 separate members of the zinc finger domain containing family: ZDHHC20, ZSCAN1, and ZNF135 on chromosomes 13, 19, and 19, respectively (Supplementary File 2).
Two microRNAs, MIR96 and MIR183, previously found to
be upregulated in glioma,29 were in close proximity to a
DMR on chromosome 7. MIR183 is reported to regulate apoptosis in several cancers including IDHmut glioma,30–32
although the role for MIR96 is less clear. β2-Spectrin, a
protein encoded by the SPTBN1 gene on chromosome 2
near another GBM DMR, is a component of TGF-β signaling
pathways that serves as a transcriptional cofactor and
adaptor protein. Recent studies have suggested a role for
β2-Spectrin in DNA repair.33

Analysis of Motifs by Glioma Molecular Subtype
and Sex
In-depth motif analysis was performed to identify
sequence-specific transcription factor (TF) binding sites
near DMPs. We first identified binding motifs significantly enriched around HyperFemale DMPs (https://data.
mendeley.com/datasets/rm588t26dp/1, Figure 5). Across
all glioma subtypes, the motif signature corresponding
to the RNA polymerase II apparatus was enriched (geometric test, P < 1e−10) near HyperFemale DMPs. Across
all non-GBMs, the motif signature for the TF E2F1 binding
site was significantly enriched (geometric test, P < 1e−11)
in areas proximal to HyperFemale DMPs. E2F1 plays a
crucial role in control of cell cycle and the action of tumor
suppressor proteins.34 The motif associated with TF NRF1
was enriched in both IDHwt non-GBMs and IDHwt GBMs
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Figure 5. Binding motifs and downstream targets for KLF6 and NFAT5, 2 GBM motifs identified by HOMER. (A) Top 5 binding motifs identified by
HOMER based on HyperMale DMPs in IDHwt GBM. (B) Transcriptional differences in KLF6 targets for female and male IDHwt GBM patients. (C)
Top 5 binding motifs identified by HOMER based on HyperFemale DMPs in IDHwt GBM. (D) Transcriptional differences in NFAT5 targets for female
and male IDHwt GBM patients. DMP, differentially methylated probes; GBM, glioblastoma.
  

(geometric test, P < 1e−12). NRF1 activates the expression of key metabolic genes that regulate cellular growth
and nuclear genes required for mitochondrial DNA transcription and replication.35 Finally, we found a number of
motifs significantly enriched in HyperFemale DMPs from
IDHwt GBM patients only. These motifs included those
associated with the TF NFAT5 (geometric test, P < 1e−22),
SMAD4 (geometric test, P < 1e−22), FOXH1 (geometric
test, P < 1e−12), proto-oncogene SPI1 (geometric test,
P < 1e−15), and CEBP (geometric test, P < 1e−12). NFAT5
plays a critical role in integrin-induced cell migration,
SMAD4 and FOXH1 are downstream mediators of TGF-β
signaling and regulate TGF-β target gene transcription,
and CEBP plays a role in immune and inflammatory response signaling.36,37
We next identified binding motifs significantly enriched near HyperMale DMPs (https://data.mendeley.
com/datasets/rm588t26dp/1, Figure 5). No binding motifs shared by all 4 glioma or non-GBM subtypes were
found. Motifs associated with TF p53, encoded by TP53,
(geometric test, P < 1e−15) and TCF7 (geometric test,
P < 1e−18) were significantly enriched in locations near

HyperMale DMPs in IDHmut non-GBMs. In IDHwt GBMs,
a number of significantly enriched motifs were identified close to HyperMale DMPs. These motifs included the
binding sequence associated with KLF6 (geometric test,
P < 1e−18) and MAC-1/ITGAM (geometric test, P < 1e−11).
KLF6 has been implicated as a tumor suppressor in multiple cancers and regulates p21 signaling. MAC-1/ITGAM
encodes the leukocyte integrin subunit α M/CD11b that has
been identified as an important regulator of apoptosis especially during brain development via the production of
microglial superoxide ions.38,39
We explored the potential effects of TF binding sites impacted by methylation in GBMs by examining the downstream target genes of KLF6 and NFAT5. KLF6 target genes
(ATG7, CDKN1A, and SMAD3), involved in apoptotic
signaling, were significantly downregulated in male IDHwt
GBM patients relative to females (Figure 5). Conversely,
the target genes of NFAT5 (CTTN and DNM2 which are involved in cell migration) were significantly downregulated
in female as compared to male GBM patients (Figure 5).
These results point to a protective effect in females via
hypermethylation of NFAT5 binding sites downregulating
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cell migration genes. In males, however, hypermethylation
of the binding sites for KLF6 appears to a deleterious effect
via the downregulation of proapoptotic genes.

Discussion
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Recent efforts in glioma research have focused on understanding the epigenetic mechanisms that lead to
gliomagenesis and that may influence treatment response.5,11,14,15 As with many cancers, males appear more
prone to develop both low- and high-grade gliomas, and
with GBM, the median survival times in males are significantly shorter than in females.1,11 This sex-based bias has
been appreciated for some time, with sex-based differences in cell cycle regulation, mitotic checkpoint signaling,
and metabolism previously described.7,40 There is growing
interest in understanding the biological mechanisms that
can explain these sex differences. For gliomas, sex-based
differences occur throughout life, suggesting that sex
hormones alone cannot account for these differences.1,11
Using data available from TCGA, we analyzed sex-based
differential methylation in all glioma molecular subtypes.
This analysis represents the first large-scale analysis of
DNA methylation in gliomas where separate but parallel
analyses were performed on male and female samples.
This approach is critical to uncovering molecular sexbased differences that influence incidence, treatment, and
outcome.
We have shown previously that sex-specific responses to
the loss of p53 function make male astrocytes more vulnerable to malignant transformation relative to female astrocytes.41 We have also shown using magnetic resonance
imaging analysis that standard treatment of temozolomide
plus concurrent radiation is more effective in female as compared to male GBM patients.7 Additionally, our previously
performed parallel analysis of transcriptomic data from
male and female GBM patients revealed sex differences that
corresponded to survival.7 In particular we showed that survival in male and female GBM patients may be dependent
on different mechanisms with better outcome in females associated with reduced integrin signaling and better outcome
in males associated with lower activity in factors that promote cell cycle progression.
Here we have extended our previous work to examine
the epigenetic differences between male and female
glioma patients, and how those differences impact downstream gene expression. We found that across glioma
subtypes the DMPs hypermethylated in females were primarily located in CpG islands, which are enriched in gene
promoter regions. Additionally, DMPs hypermethylated
in females mapped to known DHS at a higher rate than
those hypermethylated in males. DNA methylation in gene
promoters and at DHS is associated with lower transcription.42 Taken together these findings indicate an overall
downregulation of transcription in female glioma patients as compared to males. In contrast, we found that
DMPs hypermethylated in males were primarily located in
openseas regions far from gene promoters. We also found
a higher percentage of methylation in gene enhancers in
males as compared to females. The impact of methylation

in enhancer regions is not fully understood.42 These results
support our previous work that identified different, sexspecific transcriptomic mechanisms linked to survival in
GBM patients.
In addition to examining individual CpGs for differential
methylation, we determined whether each glioma subtype possessed genomic regions with sex-specific differential methylation that could lead to differences in gene
expression. Determining the functional consequences of
these DMRs requires additional study, but they do suggest intriguing candidate genes to include in future investigations. Interestingly, each molecular subtype was
characterized by a distinct set of DMRs, although some
DMRs were shared by one or more glioma subtype. The
paired box domain-containing TF PAX8 on chromosome
2 mapped to DMRs detected in both the IDHwt nonGBM and IDHmut-non-codel non-GBM subtype groups.
Previous studies in glioma biopsies and cell lines have
shown that PAX8 can regulate telomerase activity.43 Our
results suggest that, in these 2 molecular subtypes, telomerase activity might be regulated differently in males and
females and that telomerase-directed therapeutic strategies are likely to benefit either male or female patients,
but not both sexes. Perhaps more intriguing than PAX8 is
the cluster of 3 Hsp70 family members, HSPA1A, HSPA1B,
and HSPA1L, that lie in close proximity to a DMR on chromosome 6 shared by the IDHwt GBM, IDHmut-codel, and
IDHmut-non-codel molecular subtypes. Several groups
have found Hsp70 proteins to be highly expressed in highgrade gliomas,44,45 where they may aid tumor survival by
facilitating resistance to radiation46 or chemotherapy.47 Our
results indicate that targeting this chaperone may benefit
one sex preferentially.
The sex-specific survival disparity is well known in
GBMs so we focused on identifying possible DNA binding
motifs associated with dysregulated methylation that may
explain downstream transcriptomic differences. We found
the binding motif for the TF NFAT5 significantly enriched
in areas associated with DMPs hypermethylated in females. NFAT5 is a member of the Rel family of TFs, a family
that also includes NF-κB. Acting through the aquaporin-4
(AQP4) channel expressed in astrocytes, NFAT5 plays
an important role in maintaining osmotic balance in the
brain.48,49 Consistent with our previous studies implicating
reduced integrin signaling with improved survival in female GBM patients, downstream targets of NFAT5 include
genes for cytoskeletal proteins that mediate integrininduced migration. Two of these target genes, CTTN and
DNM2, were downregulated in female GBM patients relative to male GBM patients. This finding supports our hypothesis that the relative hypermethylation in females
of the NFAT5 binding site reduces expression of promigratory genes and confers a survival advantage to female GBM patients. In males, we found hypermethylation
of TF binding sites such as KLF6 and the downregulation of
the proapoptotic KLF6 targets ATG7 and CDKN1A.
These results are compelling and represent the first
un-merged sex-based analysis of glioma methylation data.
However, several limitations should be noted. First, the
sample sizes are small and we may not have accounted for
all molecular heterogeneity within each glioma subtype,
due in part to the availability of molecular features data. In
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